It is a complex, heterogeneous disease classified into hormone-receptor-positive, human epidermal growth factor receptor-2 overexpressing (HER2+) and triple-negative breast cancer (TNBC) based on histological features [35]. This evidence concerns the gene ERBB2 and triple-negative breast carcinoma.